OSWALDO A NICASTRO
Allopathic & Osteopathic Physicians|Family Medicine WILMINGTON, DE NPI 1043336613
Browse related groups: Allopathic & Osteopathic Physicians|Family Medicine DE Acerta Pharma LLC All categories
General Payments — all program years on this page
$13,059.80
- Category: General Payments
- Program years: PY2018–2024
- Record count: 623
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,868.70 across 88 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,868.70 | 88 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $259.39 | 7 |
| Lilly USA, LLC | $213.44 | 11 |
| Amgen Inc. | $158.75 | 9 |
| Novo Nordisk AS | $142.22 | 10 |
| Abbott Laboratories | $116.70 | 6 |
| Merck Sharp & Dohme Corporation | $87.37 | 3 |
| ABBVIE INC. | $76.71 | 4 |
| Exact Sciences Corporation | $71.25 | 3 |
| Insulet Corporation | $66.71 | 3 |
| GlaxoSmithKline, LLC. | $63.33 | 3 |
| SANOFI-AVENTIS U.S. LLC | $61.34 | 3 |
| Corcept Therapeutics | $55.10 | 3 |
| Mylan Specialty L.P. | $49.62 | 3 |
| Astellas Pharma US Inc | $48.29 | 2 |
| PFIZER INC. | $41.60 | 2 |
| QOL Medical, LLC | $37.64 | 1 |
| Janssen Biotech, Inc. | $31.77 | 1 |
| Radius Health, Inc. | $27.27 | 1 |
| Madrigal Pharmaceuticals | $26.68 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $22.79 | 1 |
| EISAI INC. | $22.77 | 1 |
| Phathom Pharmaceuticals, Inc. | $22.65 | 1 |
| Vanda Pharmaceuticals Inc. | $22.13 | 1 |
| DEXCOM, INC. | $21.46 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $20.88 | 1 |
| Gilead Sciences, Inc. | $20.76 | 1 |
| Medtronic, Inc. | $18.10 | 1 |
| Sumitomo Pharma America, Inc. | $17.15 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $16.67 | 1 |
| Alexion Pharmaceuticals, Inc. | $14.43 | 1 |
| Xeris Pharmaceuticals, Inc. | $13.73 | 1 |
By program year
Records — PY2024 (88)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.